Recently, the 9th Asian Winter Games came to a successful conclusion in Harbin, Heilongjiang Province. Ice and snow events have promoted the further popularization of ice and snow sports, and promoted the host city to continue and enhance the "Erbin" popularity of the previous ice and snow season.

"Erbin" not only attracted domestic and foreign tourists to the ice and snow appointment, but also promoted the development of local enterprises. Harbin Pharmaceutical Group, a listed company, is one of the beneficiaries.

Hu Xiaoping, secretary of the Party Committee of Harbin Pharmaceutical Group and chairman of Harbin Pharmaceutical Group, said in an interview with a reporter from Shanghai Securities News recently that the city's attention and recognition have increased, talents have flocked in, and corporate development has benefited accordingly.

"The city is popular, and the company will naturally benefit"

Harbin Pharmaceutical Group is the first listed company in the pharmaceutical industry in the country and the first listed company in Heilongjiang Province. It has formed a complete industrial chain layout from chemical raw materials to chemical preparations, traditional Chinese medicines, biopharmaceuticals, health foods, medical devices and other fields. It owns many well-known brands such as "Harbin Pharmaceutical", "Sanjing", "Shiyitang" and "Gai Zhonggai". The 2024 semi-annual report shows that Harbin Pharmaceutical Group has 1,802 drug approvals and 132 health product approvals.

As a local enterprise in Harbin, Harbin Pharmaceutical Group actively assumes social responsibilities and helps the city's development in many ways during the continuous popularity of "Harbin".

In the 2023-2024 ice and snow season, in combination with the company's positioning, Harbin Pharmaceutical Group opened the main building of its pharmaceutical factory No. 6 (i.e., "Harbin Pharmaceutical No. 6 Printmaking Museum") to tourists for free, and provided tourists with Chinese medicine hot drinks, warm patches, Northeast specialties and free pick-up and drop-off services; in the 2024-2025 ice and snow season, as the official non-exclusive supplier of the Asian Winter Games, Harbin Pharmaceutical Group provided the event with medicines, health foods and dietary nutritional supplements and other aspects of support.

"Harbin is popular, and our company will naturally benefit." In January 2024, when talking about the city's rapid popularity, Hu Xiaoping's pride was beyond words.

She said that she plans to combine Harbin Pharmaceutical Group's corporate development with urban tourism by relying on its old industrial brands and characteristic tourism resources. "We are very much looking forward to growing and becoming popular together with the city," she said.

"Traffic flow is cash flow"

A year later, the blueprint has gradually become a reality. Harbin Pharmaceutical Group has benefited a lot from the increasingly prosperous development of urban cultural tourism.

Harbin Pharmaceutical Group Six Prints Museum, known as the "Oriental Louvre", has become a popular check-in place on social media platforms. Data shows that since its opening in January 2024, it has received more than 2 million visitors, with a maximum daily reception of 26,000 visitors.

"Traffic flow is cash flow. At present, the average daily passenger flow of Harbin Pharmaceutical Group Six Prints Museum exceeds 10,000. We will introduce Harbin Pharmaceutical Group's product formats to deepen people's understanding of the company's products." Hu Xiaoping said.

In addition to opening Harbin Pharmaceutical Group Six Prints Museum, Harbin Pharmaceutical Group also plans to build an urban cultural tourism complex. Hu Xiaoping told reporters that the site of Harbin Pharmaceutical No. 6 Printmaking Museum was originally the Pharmaceutical Factory No. 6 under Harbin Pharmaceutical Co., Ltd. (referred to as "Harbin Pharmaceutical Factory No. 6"). In 2021, Harbin Pharmaceutical Factory No. 6 was relocated to Limin Development Zone in Harbin, and its old site on Nanzhi Road was idle as a whole. The factory covers a total area of more than 70,000 square meters and has more than 20 buildings. Currently, only part of the main building is open.

"In the past, the main idea of dealing with idle assets was to sell or rent them out. As Harbin's cultural tourism became popular in the last ice and snow season, Harbin Pharmaceutical Co., Ltd. rethought and repositioned how to revitalize its idle assets." Hu Xiaoping said that it is planned to turn part of the buildings on the Nanzhi Road site of Harbin Pharmaceutical Factory No. 6 into a comprehensive cultural tourism project with Harbin Pharmaceutical No. 6 Printmaking Museum as the main focus, and literary and artistic travel photography, architectural visits, health industry, catering and leisure and other business projects as one. At the same time, the company is preparing to attract investment to revitalize the remaining idle buildings.

"The most important thing is to practice internal skills"

In addition to using urban traffic to reach more consumers, Hu Xiaoping is more concerned about how to further enhance product strength. "The city's popularity has brought opportunities to local companies, and the most important thing is to practice internal skills." She said.

Public information shows that in terms of research and development, Harbin Pharmaceutical Co., Ltd. will focus on five major areas, including cardiovascular and cerebrovascular, digestive metabolism, respiratory, anti-infection and anti-tumor, while focusing on the layout of three directions: elderly medicine, children's medicine, and big health products. Harbin Pharmaceutical Co., Ltd. currently has five major research and development entities, and has established Harbin Pharmaceutical Big Health Research Institute, Harbin Pharmaceutical Group Technology Center and Harbin Pharmaceutical (Beijing) Biotechnology Co., Ltd., which focus on research and development in the fields of OTC, health products, generic drugs and innovative drugs. At the same time, the Chinese medicine product research and development team and the biological product research and development team focus on the upgrading of Chinese medicine products and the development of biological products, forming a diversified research and development system.

"With the help of the popularity of urban cultural tourism, Harbin Pharmaceutical Co., Ltd. introduced a number of high-level talents in the research and development sector from Shandong, Jiangsu and other places in 2024." Hu Xiaoping said that urban cultural tourism and industrial development are gradually realizing two-way empowerment.

In her opinion, as the city's attention and recognition increase, talents will flock to it, and the five-year strategic plan and product layout of Harbin Pharmaceutical Group will greatly benefit the company's development.

According to preliminary calculations, Harbin Pharmaceutical Group expects the net profit attributable to the parent company's owners in 2024 to be 544 million yuan to 653 million yuan, a year-on-year increase of 38% to 65%; the net profit attributable to the parent company's owners after deducting non-recurring items is 518 million yuan to 621 million yuan, a year-on-year increase of 59% to 91%.

As for the expected increase in performance, Harbin Pharmaceutical Group said in its communication with investors that on the one hand, the company actively adjusted its product sales structure, reshaped its product positioning and optimized its resource allocation, and at the same time steadily promoted the transformation from a heavy distribution model to a heavy terminal promotion model in stages, and carried out offline commercial performances to effectively drive performance growth; on the other hand, the company transferred back part of the bad debt provision that had been accrued to increase the current period's profit.

https://finance.eastmoney.com/a/202502203323978746.html